Thus, with continuing development on GIP/GLP-1R co-agonists modalities (Lafferty et al. 2023), it is hoped that clarity can be ascertained as to whether GIPR agonism or antagonism has the greatest role to play in management of obesity and related metabolic diseases. Here, GIPR is linked to metabolic disease.